INTRODUCTION

72
Cryptococcal meningoencephalitis (herein meningitis) is a common and lethal disease in 73 immunosuppressed patients (1, 2). This disease is predominately associated with advanced HIV 74 infection and has the highest incidence in low to middle income countries (1). The number of 75 effective agents is despairingly small (3). All available induction and maintenance regimens are Herein, we describe the in vitro activity, putative structure-activity relationships, and the 
RESULTS
106
In vitro studies 107 Flubendazole displayed potent in vitro activity in both rat and dog. In the dog, liver toxicity was also observed. As a result, the development 205 program was stopped based on an unacceptable risk/benefit profile in humans. This also halted 206 our own efforts to develop flubendazole for cryptococcal meningitis.
207
Flubendazole has striking in vitro activity against Cryptococcus neoformans that was 208 evident in the MIC testing and the pharmacodynamic studies in the hollow fiber infection model.
209
There was modest antifungal activity in the murine model, which is not as prominent as that formulation in liquid and solid phases was confirmed for 1 and 6 months, respectively.
263
A 10 mg/mL methylcellulose 4000cps stock solution (100 mL batch) was prepared from a These isolates were identified to species level using standard microbiological techniques. 
Porcine Tubulin Polymerization Assay
287
Porcine tubulin is generally used as a surrogate for human tubulin because of its high 288 degree of homology (95%) (27). In the studies described herein, this assay was used to 
294
The porcine tubulin assay was performed according to the manufacturer's instructions.
295
Briefly, the 96-well assay plate was pre-warmed to 37°C prior to use. Five μL of test every 1-min for 1-hr. at 37°C using a Varioskan multimode plate reader (Thermo scientific Inc.).
305
All data points were acquired in triplicate and IC 50 values were calculated with GraphPad Prism.
306
The IC 50 value was defined as the drug concentration required to inhibit tubulin polymerization 307 by 50% compared with negative control. hydrocortisone 10mg/kg day -1 relative to infection and then daily throughout the experiment.
389
Cryptococcal meningoencephalitis was induced with the intra-cisternal inoculation of 
396
Pharmacodynamic and Pharmacokinetic studies in Rabbits
397
PK-PD relationships in the rabbit were estimated in two independently conducted 398 experiments consisting of 6 rabbits in each experiment. Rabbits were placed under general 399 anesthesia for removal of CSF via intra-cisternal tapping at 48 hour intervals. Over the course of 400 the two experiments there were n=3 controls (1 rabbit died after being tapped), flubendazole 6 mg/kg q24h (n=6) and 22.5 mg/kg q24h (n=6). The maximum dosage that was used was limited 402 by the formulation provided by Janssen and the limits of oral gavage in rabbit (15 mL/kg/day).
403
Treatment was initiated 48 hrs. post-inoculation, and continued for 10 days, after which time all 404 rabbits were sacrificed. Thus, the total duration of the experiment was 288 hours.
406
Measurement of flubendazole concentrations using LC/MS/MS
407
Flubendazole concentrations in all matrices were measured using a validated ultrahigh- and inter-day variation was <12% for all matrices.
431
Mathematical modeling
432
The pharmacokinetic and pharmacodynamic datasets from mice were modelled using the ) are the first-order inter-compartmental rate constants. Kgmax (log 10 CFU/g/h) and kkillmax
587
(log 10 CFU/g/h) are the maximal rates of cryptococcal growth and flubendazole-induced kill, 
606
Therapy was initiated 24 hrs. post inoculation after which time Cryptococcus had grown from ~6 607 log 10 CFU/mL to 8 log 10 CFU/mL. 
